Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest gabapentin Stories

2012-09-25 10:25:22

MENLO PARK, Calif., Sept. 25, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today announced that it has filed an action in federal district court for the District of Columbia against the Food and Drug Administration, seeking an order requiring the FDA to grant Gralise(®) (gabapentin) Orphan Drug exclusivity for the management of postherpetic neuralgia (PHN). Gralise received orphan drug designation in November 2010 for the management of PHN and was approved for that use in...

2012-09-14 02:23:52

MENLO PARK, Calif., Sept. 14, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the UBS Global Life Sciences Conference in New York City. The presentation at the UBS conference is scheduled for 10:30 a.m. EDT (7:30 a.m. PDT) on Wednesday, September 19, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for...

2012-09-06 02:31:50

MENLO PARK, Calif., Sept. 6, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Morgan Stanley Healthcare Conference in New York. The 'unplugged' format at the Morgan Stanley conference is scheduled for 1:00 pm EDT (10:00 am PDT) on Wednesday, September 12. The session will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30...

2012-08-24 02:22:46

MENLO PARK, Calif., Aug. 24, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Stifel Nicolaus Healthcare Conference in Boston. The presentation at the Stifel Nicolaus conference is scheduled for 10:55 a.m. EDT (7:55 a.m. PDT) on Wednesday, September 5, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived...

2012-07-31 10:26:18

MENLO PARK, Calif., July 31, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that it has submitted a New Drug Application (NDA) for Serada to the United States Food and Drug Administration. Serada is Depomed's proprietary extended release formulation of gabapentin in development for the treatment of menopausal hot flashes. "We are pleased to achieve this milestone in our Serada program. We believe that if approved Serada will offer women a non-hormonal option for the...

2012-07-30 02:25:51

MENLO PARK, Calif., July 30, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second quarter fiscal year 2012 financial results after the market closes on Thursday, August 2, 2012. The company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a...

2012-07-23 02:25:25

MENLO PARK, Calif, July 23, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that a report of Phase 3 data published online this month, ahead of the print edition, in the Clinical Journal of Pain showed that once-daily Gralise(®) (gabapentin) tablets (1,800 mg) formulation significantly reduces intensity of pain in patients with postherpetic neuralgia (PHN). The results showed that patients treated with Gralise experienced a significant reduction (- 2.12) in...

2012-07-06 10:21:53

MENLO PARK, Calif., July 6, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the JMP Securities 7th Annual Healthcare Conference in New York City. The presentation at the JMP conference is scheduled for 10:00 am EDT (7:00 am PDT) on Friday, July 13. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days...

2012-06-21 10:26:40

MENLO PARK, Calif., June 21, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has acquired all rights to Zipsor(®) (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. The product uses proprietary ProSorb(®) delivery technology to deliver a finely dispersed, rapidly absorbed formulation of diclofenac. Zipsor,...

2012-06-19 02:27:47

MENLO PARK, Calif., June 19, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced it has received a notice of allowance from the USPTO for a patent application (Ser. No. 12/749,101) further expanding the patent portfolio around Gralise® (gabapentin), the company's once-daily product for the management of postherpetic neuralgia. The allowed patent claims include claims related to gabapentin matrix dosage forms that release gabapentin to the upper gastrointestinal tract...